Directorate Change

RNS Number : 4266S

Destiny Pharma PLC

15 November 2021

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Directorate change

Brighton, United Kingdom - 15 November 2021 -   Destiny Pharma plc (AIM: DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces  that after almost 25 years supporting the Company, Peter Morgan a Non-Executive Director,  has decided to step down from the Board with effect from 31 March 2022.  A search for a replacement is underway. 

Nick Rodgers, Chairman of Destiny Pharma, commented:

"On behalf of Destiny Pharma, I would like to thank Peter for his considerable contribution to the Company throughout its development as a private company and the transition onto the AIM market. Destiny Pharma is now in a very exciting position to deliver significant value with two late-stage clinical programmes targeting infection prevention that have delivered strong Phase 2 clinical data and are both heading towards Phase 3 clinical studies." 

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail]  

Optimum Strategic Communications 

Mary Clark / Hollie Vile / Manel Mateus

[phone]

[e-mail]  

finnCap Ltd  (Nominated Adviser and Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners  (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com  

 

END

 

 

BOABSBDBXDBDGBU